Volume 27, supplement 3, Juin 2021

Éditorial

Myeloma immunotherapy: ready for prime time (p.3-4)
Mohamad Mohty
Free Access

Revues

Anti-BCMA chimeric antigen receptor T-cell therapy in multiple myeloma: despite a strong efficacy, persistence of autologous T cells remains a major challenge (p.5-12)
Lionel Karlin
Free Access

Allogeneic chimeric antigen receptor T-cells and multiple myeloma (p.13-8)
Florent Malard
Free Access

Bispecific antibodies in myeloma (p.19-25)
Sophie Le Grand, Aurore Perrot
Free Access

Antibody-drug conjugate in multiple myeloma (p.26-34)
Escure Guillaume, Salomon Manier
Free Access